{
  "doc_id": "HTA_submission_sotosorib_FR",
  "created_date": "2022",
  "country": "FR",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "Lung cancer Sectors: City and Hospital C T RANSPARENCE OMMISSION PACKAGING NOTICE 15 JUNE 2022 sotorasib LUMYKRAS 120 mg film-coated tablet",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "Essentials",
      "text": "Notice in favour of reimbursement as monotherapy in the treatment of adult patients with advanced non-small cell lung cancer (NCBC) with the KRAS G12C mutation, whose disease has progressed after at least one previous systemic treatment line. The continuation of this opinion is conditional on the re-evaluation of this specialty within a maximum of one year on the basis of the results of the Phase III study carried out in patients with a CNBC with previously treated KRAS G12C mutation (CodeBreak 200).",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "What progress has been made?",
      "text": "No progress in the management of adult patients with advanced non-small cell lung cancer with the KRAS G12C mutation, whose disease progressed after at least one previous systemic treatment line.",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "What is the place in the therapeutic strategy?",
      "text": "The systematic research of the KRAS mutation is recommended before starting the first treatment line of the CBNPC. The prognostic or predictive value of the KRAS G12C mutation is currently poorly defined in the CBNPC, and there is no (before the provision of LUMYKRAS (sotorasib)) specific treatment targeting this mutation. The current therapeutic management of the CBNPC is identical whether or not patients have a KRAS mutation (including G12C). At the metastatic stage (IV), it is recommended to propose a systematic second-line treatment, whether or not patients have responded to a 1st metastatic line. The nature of this treatment depends on the molecules used previously, the ECOG score and histology: - Patients treated with immunotherapy in 1st line: chemotherapy based on platinum salts, as in 1st line: cisplatin-vinorelbine, cisplatin-gemcitabine, carboplatin-paclitaxel, cisplatin-docetaxel, cisplatin-pepiderexed only)",
      "start_page": 2,
      "end_page": 3
    },
    {
      "heading": "ASMR",
      "text": "ISP Place in Therapeutic Strategy Population HAS - Directi Notice version xame la que target ion d n defin en Registration In monotherapy in the treatment of adult patients with advanced non-small cell bronchial cancer (NCBC) with the KRAS G12C mutation, whose disease has progressed after at least one previous systemic treatment line LOW The continuation of this opinion is conditioned by the re-evaluation of this specialty within a maximum of one year on the basis of the results of the Phase III study carried out in patients with previously treated KRAS G12C with a CBNPC mutation (Break Code 200). Considering: - the poor quality of the demonstration of the efficacy of LUMYKRAS (sotorasib), based on data from a non-comparative phase I/II study; - the poorly defined prognostic and predictive value of the KRAS G12C mutation",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "does not improve the medical service rendered (ASMR V) in the intake",
      "text": "LUMYKRAS (sotorasib) is not likely to have an additional impact on public health Despite the low level of evidence, and pending new efficacy and safety data, the Commission considers that LUMYKRAS (sotorasib), as monotherapy, is a treatment option in the management of adult patients with advanced non-small cell bronchial cancer (NCPC) with the KRAS G12C mutation, whose disease has progressed after at least one previous systemic treatment line Given the currently poorly defined prognostic and predictive value of the KRAS G12C mutation in CBNPC, and the lack of an acceptable methodologically comparable data, the place of LUMYKRAS (sotorasib) vis-à-vis available therapeutic alternatives (chemiotherapy, immunotherapy)",
      "start_page": 3,
      "end_page": 7
    },
    {
      "heading": "TAXOL",
      "text": "(paclitaxel) BMS and In combination with cisplatin, generic: in the CBNPC for which Accord, Arrow, a potentially non-Celgene, EG, curative and/or Hospira, Kabi, radiotherapy is not Mylan, indicated Ratiopharm, Teva, Sandoz TAXOTERE In combination with cisplatin, (docetaxel) in the CBNPC non-Sanofi and resectable, locally generic: advanced or metastatic, Non Accord, Amring, in patients not having Arrow, Ebewe, receiving EG chemotherapy, Hospira, anterior Kabi, Pfizer ALIMTA Second-level monotherapy No (pemetrexed) CBNPC line, when HAS - Evaluation and Metastatic Directorate, Amring, in patients not having Arrow, Ebewe, receiving EG chemotherapy, Hospira, anterior Kabi, Pfizer ALIMTA Second-level monotherapy No (pemetrexed) CBNPC line, when HAS - Assessment and Access to l-Innovatio Date NA",
      "start_page": 7,
      "end_page": 8
    },
    {
      "heading": "TECENTRIQ",
      "text": "or metastatic after an exception (atezolizumab) No previous chemotherapy of Roche patients ALK+) Squad CBNPC 03/02/2016 Important ASMR III (moderate) compared to locally advanced docetax or (registration) metastatic after prior chemotherapy OPDIVO (nivolumab) No non-epidermoid CBNPC 11/01/2017 Important ASMR IV (minor) compared to locally advanced or (registration) BMS docetax (only metastatic) after prior chemotherapy patients ECOG 0 or CBNPC locally advances 03/03/2021 Important ASMR IV (minor) compared to docetax or metastatic, with PD-L1 (reassessment) (to",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "KEYTRUDA",
      "text": "≥ 1%, and having received at least the exception (pembrolizumab) Not chemotherapy of previous MSD patients ALK+) *pharmaceutical-therapeutic class; 的 registered before the decree of 1999 governing MRS and ASMR GEMZAR (gemcitabine) and AVASTIN (bevacizumab) specialties are used off-MAH in 2nd line and more and AURA recomman); they are retained as clinically relevant comparators. xel xel xel xel ndées (r Yes Yes Yes Yes recommendation Non-medicinal comparators Support care.",
      "start_page": 8,
      "end_page": 9
    },
    {
      "heading": "Conclusion",
      "text": "The clinically relevant comparators of LUMYKRAS (sotorasib) in the indication of the evaluated MAH are the medicinal products listed in the table above, as well as the speciality GEMZAR (gemcitabine) and AVASTIN (bevacizumab), in the context of non-MAH use for the latter two.",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "INTERNATIONAL",
      "text": "AMM in the United States The LUMYKRAS (sotorasib) specialty has an AMM in the United States with a superimposed wording \"treatment of adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, which have received at least one prior system therapy\".",
      "start_page": 9,
      "end_page": 10
    },
    {
      "heading": "7.1.1 CodeBreak Study 100",
      "text": "A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effectiveness of AMG 510 Reference Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation Clinicaltrials.gov Registration No.: NCT03600883 Main objective to estimate the objective response rate, evaluated by an independent review committee, in adults with advanced solid tumour with mutation KRAS G12C Phase I/II \"basket\" study, non-comparative Study Type of study Date of first patient included: 13/08/2019 Date of last patient included: 05/02/20 Date and duration of date of data extraction for main analysis: 05/09/2020 Study Study conducted in 59 centres in 11 countries (including 4 centres in France with 19 patients) - age ≥ 18 years - advanced solid mutation KRAS - K12",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "Study diagram",
      "text": "The safety follow-up takes place 30 (+7) days after the end of treatment. Long-term follow-up of overall survival is carried out every 12 weeks. Patients received LUMYKRAS (sotorasib) orally (tablets), 960 mg once daily. Treatment was continued until disease progression, Treatments studied patient cessation decision, death, loss of sight, sponsor's decision, non-compliance, pregnancy, adverse event, intolerance, need for a therapeutic alternative. Objective response rate evaluated by an independent review committee according to Criterion of judgement the criteria RECIST 1.1 and defined as the proportion of patients with a complete or partial primary response. This response was to be confirmed by a second imaging performed at least 4 weeks after. - duration of response: delay between the first partial or complete response and the first relapse or progression (criteria RECIST 1.1) or death",
      "start_page": 10,
      "end_page": 11
    },
    {
      "heading": "Results:",
      "text": "In total, 224 patients were included in this \"basket\" trial: 126 patients with NSCLC, 62 patients with colorectal cancer and 36 patients with another type of cancer. Only 126 patients in the NSCLC cohort will be described in the follow-up to this advisory. 的 Analyses and gels of data - Data from 01/09/2020: corresponding to the main efficacy analysis of the study. - Data from 01/12/2020 and 15/03/2021: corresponding to the follow-up data, exploratory Number of previous lines, n (%) Type of previous treatment*, n (%) Chimotherapy 115 (91%) Immunotherapy 116 (92%) Targeted therapy 30 (24%) Stage of inclusion, n (%) III 5 (4%) IV 121 (96%) Histology, n (%) Epidermoid 1 (1%) Non-epidermoid 125 (99%) Mutations*, n (%) KRAS 126 (100%) EGFR 3 (2%) MET 2 (1%) TP53 13 (10%) STK11 7 (6%) Metastases*, n (%) Hepatic 26 (21%)",
      "start_page": 11,
      "end_page": 13
    },
    {
      "heading": "Table 2. Exploratory Secondary Judgement Criteria for the CodeBreak Study 100",
      "text": "Data Freeze Data Freeze from 01/12/2020 01/09/2020 data N=124 15/03/2021 N=123 N=124 Follow-up, month Median (min-max) 9.3 (1.1-12.2) 12.2 (1.1-5.6) 15.3 (1.1-18.4) Duration of response, month Median [IC95%] 8.4 [6.9-8.4] 10.0 [6.9-11.1] 11.1 [6.9-NE] Rate of disease control, n(%) % [IC95%] 81% [72-87] 81% [73-87] 81% [73-87] Time to response, month Median (min-max) 1.4 (1.2-6.1) 1.4 (1.2-10.1) 1.4 (1.2-10.1) Survival without progression, month Median [IC95%] 6.7 [4.9-8.1] 6.8 [5.1-8.2] 6.8 [5.1-8.2] Overall Survival, month Median [IC95%] 12.0 [9.5-NE] 12.5 [10.0%-NE] 12.5 [10.0%-NE]",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "7.1.2 Indirect comparison data",
      "text": "An indirect comparison was made between patients in the CodeBreak 100 study treated with sotorasib, and patients in the ESME cohort treated with standard treatments. The individual data were available for the CodeBreak 100 study. For the ESME cohort, only aggregated data were available.",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "This indirect comparison, however, has methodological limitations.",
      "text": "- the absence of residual confusion, a hypothesis necessary for this type of method, cannot be ensured: o the princeps analysis, since three prognostic variables, whereas other confounding factors had been listed a priori; o the consideration of the 11 confounding factors measured in another analysis, leads to an effective small sample size (effective sample size) which does not allow for an accurate or even valid estimate of the effect of treatment; o there appears to be unmeasured confounding factors (albuminemia, liver function, renal function, LDH, delay since the last treatment line): these potential confounding factors not being recorded (or missing too large data) in the ESME cohort; o patients with active brain metastases (excluding CodeBreak 100, at a more unfavourable prognosis) have not been excluded from the ESME cohort (information on",
      "start_page": 13,
      "end_page": 14
    },
    {
      "heading": "7.3.1 Data from the CodeBreak study 100",
      "text": "The safety data described are those from the base gel of March 15, 2021, allowing the largest decline. The tolerance population was 126 patients. As of March 15, 2021, the median duration of treatment with sotorasib was 24 weeks (min-max: 1-77). Almost all patients reported an adverse event (AE) (99%). The proportion of AEs of grades ≥ 3 was 61%. The proportion of serious AEs was 55%. The proportion of AEs leading to discontinuation of treatment with sotorasib was 9%. The proportion of AEs moving towards death was the most frequent AEs are detailed in the table below. Table 3. The most common adverse events in the CodeBreak 100 AE study of all AEs of grades ≥ 3 Diarrhoea 64 (51%) 7 (6%) Nausea 39 (31%) 1 (1%) Fatigue 32 (25%) 3 (2%)",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "7.3.2 Risk Management Plan (RMP) Data",
      "text": "The risk summary of the LUMYKRAS (sotorasib) RMP (version 0.3 of September 28, 2021) is presented in the table below: Significant Risks Identified - No Potential Significant Risks - No Missing Information - Use in patients with hepatic impairment",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "Data from PSURs",
      "text": "The PBRER/PSUR (Periodic Benefit-Risk Evaluation Report/Periodic Safety Update Report) covering the period from 21 May 2021 to 27 November 2021 was provided. During this period, a signal on interstitial pneumonitis was analysed and considered to be a significant risk identified.",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "Data from SPC",
      "text": "\"4.4 Special warnings and precautions for use Hepatotoxicity Sotorasib may cause hepatotoxicity, which may result in hepatic lesions of drug origin or hepatitis. Sotorasib has been associated with transient elevations in serum transaminase levels (ALT and AST). These elevations have been reduced or resolved by dose adjustment or permanent discontinuation of treatment and have resulted in no hepatic impairment or death in clinical studies. Of patients with hepatotoxicity, 38% had hepatotoxicity that resulted in discontinuation of treatment or dose reduction. Overall, 26% of patients with hepatotoxicity received corticosteroids concomitantly. Increases in liver enzymes may be asymptomatic. Patients should be monitored for hepatic function (ALT, AST and total bilirubin) prior to initiation of treatment with LUMYKRAS every 3 weeks during the first 3 weeks. Patients should be monitored for hepatic function (ALT, AST and total bilirubin) prior to initiation of therapy with LUMYKRAS, every 3 weeks during the first 3 weeks.",
      "start_page": 15,
      "end_page": 19
    },
    {
      "heading": "Public health interest",
      "text": "Given: - the severity of the disease, - the partially covered medical need, - the lack of additional response to the identified need, in the absence of demonstrated impact on morbi-mortality and quality of life, - the lack of data to assess any additional impact on the care and/or life course.",
      "start_page": 19,
      "end_page": 20
    },
    {
      "heading": "Taking into account:",
      "text": "- the poor quality of the demonstration of efficacy of LUMYKRAS (sotorasib), based on data from a non-comparative Phase I/II study; - the poorly defined prognostic and predictive value of the KRAS G12C mutation in CBNPC; - the uncertainty about the relative effectiveness of this treatment, considering the lack of direct comparison and the methodological weakness of the indirect comparison provided, in a context where direct comparison with a therapeutic alternative available with a robust methodology is possible, - the safety profile, marked by the incidence of serious adverse events (AEs) reported in more than half of patients (55%) and that of AIs ≥ 3 in nearly two thirds of patients (61%) the Transparency Commission considers that LUMYKRAS (sotorasib) does not contribute to the improvement of medical service rendered (ASMR V) in management",
      "start_page": 20,
      "end_page": 21
    },
    {
      "heading": "External expertise",
      "text": "No Presentations LUMYKRAS 120 mg film-coated tablets concerned Box of 240 film-coated tablets (CIP: 34009 302 419 3 6) Applicant Amgen SAS Social Security (CSS L.162-17) Lists concerned Communities (CSP L.5123-2) Initial date: 06/01/2022 (centralized procedure) conditional MA associated with a PGR Specific post-authorization requirement for conditional MA: In order to further confirm the efficacy and safety of sotorasib in the MA treatment of patients with advanced non-small cell bronchial cancer (NCBC) with KRAS G12C mutation, the MAH must submit the clinical study report for the primary Phase III study CodeBreak 200 (study 20190009) comparing sotorasib with docetaxel for the treatment of advanced KRAS G12C mutation previously treated. The clinical study report will be submitted before: 31/03/2023 ATU nominative (first application validated by l",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "table underheading <的 Which place in the therapeutic strategy?>",
      "text": "Row 1:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "table underheading <n的 does not bring improvement of the medical service rendered (ASMR V) in the intake>",
      "text": "Row 1: Reason for Examination:Inscription: Row 2: Relevant indication:In monotherapy in the treatment of adult patients with cancer: Row 3::; advanced non-small cell bronchial (NCCB) with KRAS: Row 4::G12C mutation, whose disease has progressed after at least one treatment line: Row 5:; anterior systemaemic: Row 6: SMR:FAIBLE: Row 7:; maintenance of this opinion is conditioned on the re-evaluation of this specialty: Row 8:; within a maximum of one year on the basis of the results of the phase study: Row 9:; III performed in patients with a CBNPC with the mutation: Row 10:;KRAS G12C previously treated (CodeBreak 200).: Row 11: ASMR:Accounted::: Row 12:; poor quality of the demonstration of the efficacy of LUMYKRAS: Row 13:;(sotorasib), based on data from a phase study of I/II:",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table underheading <n的 does not bring improvement of the medical service rendered (ASMR V) in the intake>",
      "text": "Row 1: Indication Row 2: concerned",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table underheading <n的 does not bring improvement of the medical service rendered (ASMR V) in the intake>",
      "text": "Row 1: Place in Row 2: Row 3: therapeutic strategy",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table underheading <n的 does not improve the medical service rendered (ASMR V) in the intake> (column 1)",
      "text": "Row 1: Pattern of the ex Row 2: Indication concerned Row 3: SMR Row 4: ASMR Row 5: ISP Row 6: Place in the therapeutic strategy Row 7: Population",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table underheading <n的 does not improve the medical service rendered (ASMR V) in the intake> (column 1)",
      "text": "Row 1: Place in Row 2: Row 3: Therapeutiq strategy",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table underheading <n的 does not improve the medical service rendered (ASMR V) in the intake> (column 2)",
      "text": "Row 1: xame Row 2: Row 3: Row 4: Row 5: Row 6: Row 7: Row 8: Row 9: Row 10: Row 11: Row 12: Row 13: Row 14: Row 15: Row 16: Row 17: Row 18: as Row 19: Row 20: target",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table underheading <n的 does not improve the medical service rendered (ASMR V) in the intake> (column 3)",
      "text": "Row 1: en的Registrations of the KRAS-Row::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table underheading <n的 does not improve the medical service rendered (ASMR V) in the intake> (column 3)",
      "text": "Row 1: Row 2:",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table underheading <n的 does not improve the medical service rendered (ASMR V) in the intake> (column 3)",
      "text": "Row 1: Row 2: Row 3:",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "table underheading <TAXOL>",
      "text": "Row 1: NAME (INN) Laboratory",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <TAXOL>",
      "text": "Row 1: NAME Row 2: (INN) Row 3: Laboratory",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <TAXOL>",
      "text": "Row 1: Take Row 2: in Row 3: charge",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <TAXOL>",
      "text": "Row 1: SMR Row 2:",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <TAXOL>",
      "text": "Row 1: ASMR Row 2: (Lébellé)",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <TAXOL> (column 1)",
      "text": "Row 1: NAME (INN) Laboratoires---- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <TAXOL> (column 2)",
      "text": "Row 1 :Date of theav",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <TAXOL> (column 3)",
      "text": "Row 1: screws & screws & screws & screws & screws & screws & screws & screws & screws & screws & screws & screws & screws & screws & screws & screws & screws & screws & screws & screws",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <TAXOL> (column 3)",
      "text": "Row 1: Row 2:",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <TAXOL> (column 4)",
      "text": "Row 1: Row 2: Row 3: Row 4:",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <TAXOL> (column 6)",
      "text": "Row 1: Row 2: AS Row 3: (Lib Row 4:",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <TAXOL> (column 7)",
      "text": "Row 1: Row 2: SMR Row 3: belled) Row 4:",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <TAXOL> (column 10)",
      "text": "Row 1:1:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "table underheading <KEYTRUDA>",
      "text": "Row 1: Lilly and generics: Kabi, Mylan, Ohre, Zentiva, and that histology is not predominantly epidermoid-dominated------ -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "table underheading <KEYTRUDA> (column 1)",
      "text": "Row 1: Lilly and generics: Kabi, Mylan, Ohre, Zentiva--that histology is not predominantly epidermoid--Row 2: TECENTRIQ (atezolizumab) Roche------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "table underheading <KEYTRUDA> (column 3)",
      "text": "Row 1: Row 2: Yes Row 3: Yes Row 4: Yes",
      "start_page": 8,
      "end_page": 8
    },
    {
      "heading": "table underheading <INTERNATIONAL>",
      "text": "Row 1: Countries--- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "start_page": 9,
      "end_page": 9
    },
    {
      "heading": "table underheading <Schedule of the study>",
      "text": "Row 1: Footnotes & References: 1/2, Open-label Study evaluating the Safety, Tolerability, &h;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "table underheading <Schedule of the study>",
      "text": "Row 1: Date and Duration of Row 2: Study",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "table underheading <Schedule of the study>",
      "text": "Row 1: Main criteria Row 2: inclusion",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "table underheading <Schedule of the study>",
      "text": "Row 1: Key criteria Row 2: Not to be included",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "table underheading <Results :>",
      "text": "Row 1: Primary Judgement Criterion:Objective response rate assessed by an independent review committee according to RECIST criteria 1.1 and defined as the proportion of patients with a complete or partial response.This response was to be confirmed by a second imaging performed at least 4 weeks later. Row 2: Key secondary judgement criteria: response time between the first partial or complete response and the first relapse or progression ( RECIST criteria 1.1) or death all cause - disease control rate: proportion of patients with a complete, partial or stable response ≥ 5 weeks - delay until response: delay between the start of treatment and the first partial or complete response - progression-free survival, evaluated by an independent review committee: delay between initiation of treatment and progression or death all cause -",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "table underheading <Results :>",
      "text": "Row 1: Row 2: Main Judgement Criterion",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "table underheading <Results :>",
      "text": "Row 1: Key Criteria Row 2: Judgment Row 3: Secondary Row 4: Row 5: Row 6: Row 7:",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "table underheading <Results :>",
      "text": "Row 1: Row 2: results analysis method",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "table underheading <Results :> (from previous page)",
      "text": "Row 1:-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "Table 2. Exploratory Secondary Judgement Criteria for the CodeBreak Study 100",
      "text": "Row 1:1:-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "Table 2. Exploratory Secondary Judgement Criteria for the CodeBreak Study 100",
      "text": "Row 1: Row 2: data freeze from 01/12/2020 Row 3: N=124",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "table underheading <7.3.2 Risk Management Plan (RMP) data>",
      "text": "Row 1:-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- --",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "table underheading <7.3.2 Risk Management Plan (RMP) data>",
      "text": "Row 1: EI of all Row 2: grades",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "table underheading <7.3.2 Risk Management Plan (RMP) data>",
      "text": "Row 1: IE Rank 2: ≥ 3",
      "start_page": 14,
      "end_page": 14
    },
    {
      "heading": "table underheading <7.3.4 SPC data> (from previous page)",
      "text": "Row 1:的Name of the Study Schema,Availability of Row 2:的l-Study,How to Data,How to Use Row 3: CodeBreak 200--Phase III, randomized, open-label versus docetaxel, in adult patients with advanced KNPC with KRAS G12C mutation, previously treated,End 2022 - Early 2023--Row 4: IFCT-2012 Lung KG12--Ci--A retrospective observational study including patients treated with ATUc--Fin 2022---Row 4: IFCT-2012 Lung KG12--------------------------------------------------------------------------------------------------------------------------------------------------------------------",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "table underheading <External expertise>",
      "text": "Row 1: Schedule of Assessment: Date of Administrative Validation*: 07/02/22 Date of Review: 20/04/2022 Date of Adoption: 11/05/2022 Date of Laboratory Hearing: 15/06/2022 Row 2: Stakeholders (including patient and user associations): Yes Row 3: External Expertise: No Row 4: Relevant Presentations: LUMYKRAS 120 mg, film-coated tablet Box of 240 film-coated tablets (CIP: 34009 302 419 3 6) Row 5: Applicant: Amgen SAS Row 6: Relevant Lists: Social Safety (CSS L.162-17) Communities (CSP L.5123-2) Row 7: AMMs: Initial Date: 06/01/2022 (centralized procedure) conditional AMM associated with a PMP Specific Post-Authorization Obligation for Conditional AMM: In order to further confirm the efficacy and safety of sotorasib in the treatment of patients with advanced non-small cell bronchial cancer (NSCC) with KRAS G12C mutation, the holder of the clinical review shall submit the clinical review phase of the clinical review phase of the review of the submission.",
      "start_page": 21,
      "end_page": 21
    }
  ]
}